-Reuters
Barclays Maintains Overweight on DT Midstream, Raises Price Target to $62
Barclays analyst Theresa Chen maintains DT Midstream (NYSE:DTM) with a Overweight and raises the price target from $59 to $62.
Related Posts
Teva Presents New Data Supporting Safety, Tolerability And Target Engagement Of Anti-TL1A Antibody At The 2024 ECCO Annual Meeting
Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A (TEV-'574)1Anti-TL1A (TEV-'574) was shown to be safe and well-tolerated, with a low incidence of antidrug
Twitter Rolls Out Encrypted DMs As Musk Promised — But They’re Not Free
As promised, Elon Musk’s Twitter has launched end-to-end encryption for direct messages — but only for verified subscribers. What Happened: Twitter has limited…
Lowe’s On Right Track With Its Long-Terms Goals In Place, Says Analyst
Telsey Advisory Group analyst Joseph Feldman reiterates an Outperform rating on the shares of Lowe’s Companies Inc (NYSE:LOW) and lowered the price target…